Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib

References

• Li Y, Yang D, Yang S. Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma. Evid Based Complement Alternat Med. 2021;2021:8793187. doi:10.1155/2021/8793187
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B. Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol. 2013;37(4):374–377. doi:10.1016/j.canep.2013.03.008
   PubMed Web of Science ®Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8–13. doi:10.1177/107327480901600102
   PubMed Web of Science ®Google Scholar
• Fong P, Meng LR. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. Med Sci Monit Basic Res. 2014;20:146–152. doi:10.12659/MSMBR.892514
   PubMedGoogle Scholar
• Husing A, Dossus L, Ferrari P, et al. An epidemiological model for prediction of endometrial cancer risk in Europe. Eur J Epidemiol. 2016;31(1):51–60. doi:10.1007/s10654-015-0030-9
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105–S143. doi:10.1016/s0020-7292(06)60031-3
   Web of Science ®Google Scholar
• Davidson BA, Moss HA, Arquiette J, Kamal AH. Top Ten Tips Palliative Care Clinicians Should Know When Caring for Patients with Endometrial Cancer. J Palliat Med. 2018;21(6):857–861. doi:10.1089/jpm.2018.0053
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Gibbons SK, et al. A randomized Phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112(3):543–552. doi:10.1016/j.ygyno.2008.11.014
   PubMed Web of Science ®Google Scholar
• Barrington DA, Dilley SE, Smith HJ, Straughn JM. Pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis. Gynecol Oncol. 2019;153(2):381–384. doi:10.1016/j.ygyno.2019.02.013
   PubMed Web of Science ®Google Scholar
• Lemaitre C, Soutoglou E. Double strand break (DSB) repair in heterochromatin and heterochromatin proteins in DSB repair. DNA Repair. 2014;19:163–168. doi:10.1016/j.dnarep.2014.03.015
   PubMed Web of Science ®Google Scholar
• Caldecott KW. DNA single-strand break repair. Exp Cell Res. 2014;329(1):2–8. doi:10.1016/j.yexcr.2014.08.027
   PubMed Web of Science ®Google Scholar
• Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood J Am Soc Hematol. 2010;116(22):4578–4587.
   Google Scholar
• Amé JC, Spenlehauer C, De Murcia G. The PARP superfamily. Bioessays. 2004;26(8):882–893.
   PubMed Web of Science ®Google Scholar
• Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature. 1992;356(6367):356–358. doi:10.1038/356356a0
   PubMed Web of Science ®Google Scholar
• Philip CA, Laskov I, Beauchamp MC, et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017;17(1):638. doi:10.1186/s12885-017-3639-0
   PubMedGoogle Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Amin O, Beauchamp MC, Nader PA, et al. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. BMC Cancer. 2015;15:817. doi:10.1186/s12885-015-1803-y
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–251. doi:10.1016/s0140-6736(10)60893-8
   PubMed Web of Science ®Google Scholar
• Miyasaka A, Oda K, Ikeda Y, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014;14:179. doi:10.1186/1471-2407-14-179
   PubMed Web of Science ®Google Scholar
• Ren Y, Song Z, Rieser J, et al. USP15 Represses Hepatocellular Carcinoma Progression by Regulation of Pathways of Cell Proliferation and Cell Migration: a System Biology Analysis. Cancers. 2023;15(5):1371. doi:10.3390/cancers15051371
   PubMed Web of Science ®Google Scholar
• Perkhofer L, Gout J, Roger E, et al. DNA damage repair as a target in pancreatic cancer: state-of-The-art and future perspectives. Gut. 2021;70(3):606–617.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588–5599. doi:10.1158/0008-5472.CAN-12-2753
   PubMed Web of Science ®Google Scholar
• Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39(25):4869–4883. doi:10.1038/s41388-020-1328-y
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi:10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol. 2011;8(5):302–306. doi:10.1038/nrclinonc.2011.42
   PubMed Web of Science ®Google Scholar
• Min A, Im SA, Yoon YK, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther. 2013;12(6):865–877. doi:10.1158/1535-7163.Mct-12-0950
   PubMed Web of Science ®Google Scholar
• Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1(3):179–186. doi:10.1038/35043058
   PubMed Web of Science ®Google Scholar
• Riches LC, Trinidad AG, Hughes G, et al. Pharmacology of the ATM Inhibitor AZD0156: potentiation of Irradiation and Olaparib Responses Preclinically. Mol Cancer Ther. 2020;19(1):13–25. doi:10.1158/1535-7163.Mct-18-1394
   PubMed Web of Science ®Google Scholar
• Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO j. 2003;22(20):5612–5621. doi:10.1093/emboj/cdg541
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499–506. doi:10.1038/nature01368
   PubMed Web of Science ®Google Scholar
• Zhang W, Shi J, Li R, et al. Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation. Oncologist. 2020;25(5):375–379. doi:10.1634/theoncologist.2019-0498
   PubMed Web of Science ®Google Scholar
• Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004;64(24):9152–9159. doi:10.1158/0008-5472.CAN-04-2727
   PubMed Web of Science ®Google Scholar
• Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33(15):2413–2415. doi:10.1093/bioinformatics/btx162
   PubMed Web of Science ®Google Scholar
• Rütten H, Verhoef C, van Weelden WJ, et al. Recurrent Endometrial Cancer: local and Systemic Treatment Options. Cancers (Basel). 2021;13(24). doi:10.3390/cancers13246275
   PubMed Web of Science ®Google Scholar
• Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354–361. doi:10.1093/jnci/djx214
   PubMedGoogle Scholar
• Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol. 2016;34(35):4225–4230. doi:10.1200/jco.2016.69.4638
   PubMed Web of Science ®Google Scholar
• Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer. 2020;30(2):193–200. doi:10.1136/ijgc-2019-000822
   PubMed Web of Science ®Google Scholar
• Del Carmen MG, Boruta DM, Schorge JO. Recurrent endometrial cancer. Clin Obstet Gynecol. 2011;54(2):266–277. doi:10.1097/GRF.0b013e318218c6d1
   PubMed Web of Science ®Google Scholar
• Pilié PG, Tang C, Mills GB, Yap TA. State-of-The-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.
   PubMed Web of Science ®Google Scholar
• Mak JPY, Ma HT, Poon RYC. Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G(2) DNA Damage Checkpoint. Mol Cancer Ther. 2020;19(1):123–134. doi:10.1158/1535-7163.Mct-19-0474
   PubMed Web of Science ®Google Scholar
• Williamson CT, Muzik H, Turhan AG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010;9(2):347–357. doi:10.1158/1535-7163.Mct-09-0872
   PubMed Web of Science ®Google Scholar
• Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib. Transl Oncol. 2017;10(2):190–196. doi:10.1016/j.tranon.2017.01.007
   PubMed Web of Science ®Google Scholar
• Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: therapeutic Implications. Mol Cancer Ther. 2016;15(8):1781–1791. doi:10.1158/1535-7163.Mct-15-0945
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49–58. doi:10.1016/j.ejca.2016.03.005
   PubMed Web of Science ®Google Scholar
• Guo X, Yang C, Qian X, et al. Estrogen receptor alpha regulates ATM Expression through miRNAs in breast cancer. Clin Cancer Res. 2013;19(18):4994–5002. doi:10.1158/1078-0432.CCR-12-3700
   PubMed Web of Science ®Google Scholar
• Lung RW, Hau PM, Yu KH, et al. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. J Pathol. 2018;244(4):394–407. doi:10.1002/path.5018
   PubMed Web of Science ®Google Scholar
• Hong R, Ma F, Zhang W, et al. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer. 2016;16(1):725. doi:10.1186/s12885-016-2754-7
   PubMedGoogle Scholar